Critical Review: Mannatech (NASDAQ:MTEX) versus CDT Equity (NASDAQ:CDT)

Mannatech (NASDAQ:MTEX) and CDT Equity (NASDAQ:CDT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations for Mannatech and CDT Equity, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mannatech	1	0	0	0	1.00
CDT Equity	1	0	0	0	1.00

Risk and Volatility

Mannatech has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, CDT Equity has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500.

Profitability

This table compares Mannatech and CDT Equity’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mannatech	-11.97%	-496.67%	-39.51%
CDT Equity	N/A	-4,263.33%	-529.91%

Earnings and Valuation

This table compares Mannatech and CDT Equity”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mannatech	$108.04 million	0.08	-$15.21 million	($8.00)	-0.53
CDT Equity	N/A	N/A	-$39.22 million	($66,338.55)	0.00

Mannatech has higher revenue and earnings than CDT Equity. Mannatech is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

13.0% of Mannatech shares are held by institutional investors. Comparatively, 3.3% of CDT Equity shares are held by institutional investors. 41.5% of Mannatech shares are held by company insiders. Comparatively, 10.8% of CDT Equity shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Mannatech beats CDT Equity on 7 of the 10 factors compared between the two stocks.

About Mannatech

Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.

About CDT Equity

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.